- | Aptinyx
Treating the Brain to Address Long-Term Chronic Pain with Andy Kidd MD Aptinyx
Andy Kidd MD is the President and COO and soon to be CEO of Aptinyx. With a focus on Pain Awareness Month, Andy provides a view into the world of treating long-term chronic pain and the necessary innovations to treat the cause of chronic pain in conditions like diabetic peripheral neuropathy and fibromyalgia.
- | Recce Pharmaceuticals
PharmaShots Interview: Recce Pharmaceuticals’ James Graham Shares Insight on the P-I/II Clinical Trial of RECCE 327 (R327) for Infected Burn Wounds
In an interview with PharmaShots, James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds.
- | AltruBio
AltruBio snags a CMO after pivot from oncology to immunology
AltruBio has signed a new chief medical officer, five months after a makeover that saw it change its name, its focus and its board.
- | Cardiff Oncology
Cardiff reveals early data on challenger to Amgen’s KRAS crown
Cardiff’s onvansertib is being trialed in a phase 1b/2 study in patients with metastatic colorectal cancer who have a mutation of the KRAS gene, according to a Wednesday release. The therapy is being combined with chemotherapy and Roche’s stalwart Avastin. Patients must have failed on chemotherapy and or/Avastin prior to entry in the trial.
- | IMV Inc.
The Search Intensifies for Cancer Treatments with Fewer Side Effects
Dorigo is principal investigator of a clinical trial of a new immunotherapy called maveropepimut-S. It’s being developed by IMV Inc., a pharmaceutical company focused on innovative immune cell activating approaches.
- | Araris Biotech
New ADC Linker Tech Shows Efficacy, Safety Advantages
At the heart of Araris’ platform is its proprietary line of indication-specific peptide linkers with finely tuned hydrophilicity to accommodate various payloads, composed from an enzyme that’s already been approved by the FDA for food use. A native glycosylated antibody, the Araris linker with the payload, bind to form the ADC under the catalyzing effect of the enzyme.
- | ProQR
Eli Lilly bets on an RNA base editing outfit leveraging the body’s own enzymes to reverse mutations
With its controversial Alzheimer’s med donanemab nearly ready for FDA scrutiny, Eli Lilly has grown more emboldened in its efforts to become the top dog in neuroscience. A new partnership with a quiet RNA editing player focused around neuroscience could now add even more bite to Lilly’s bark.
- | SOTIO
CTO Shares Secrets To A Successful Cell & Gene Therapy Supply Chain Strategy
“It’s not exactly rocket science,” Ludek Sojka, CTO, SOTIO, admitted during our conversation on managing raw material supplier relationships to better control overall C&G therapy COGS. However, the past year has proven that securing a reliable supply of raw materials will — despite our best intentions — always be an evergreen challenge. A great reminder of this came in the form of a survey earlier this year revealing that dual-source supply chains — though they are regularly heralded as essential — still remain mythical for 50 percent of advanced therapy survey respondents.
